JP6158077B6 - ヘルペス感染症の予防措置及び治療措置のためのピロキシカム - Google Patents
ヘルペス感染症の予防措置及び治療措置のためのピロキシカム Download PDFInfo
- Publication number
- JP6158077B6 JP6158077B6 JP2013503032A JP2013503032A JP6158077B6 JP 6158077 B6 JP6158077 B6 JP 6158077B6 JP 2013503032 A JP2013503032 A JP 2013503032A JP 2013503032 A JP2013503032 A JP 2013503032A JP 6158077 B6 JP6158077 B6 JP 6158077B6
- Authority
- JP
- Japan
- Prior art keywords
- drug
- piroxicam
- herpes
- preventive
- therapeutic measures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims description 11
- 229960002702 piroxicam Drugs 0.000 title claims description 10
- 206010019973 Herpes virus infection Diseases 0.000 title description 5
- 230000003449 preventive effect Effects 0.000 title description 3
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 208000009889 Herpes Simplex Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 208000004898 Herpes Labialis Diseases 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 229960001259 diclofenac Drugs 0.000 description 5
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960004752 ketorolac Drugs 0.000 description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YNPZRWAUSSZALM-UHFFFAOYSA-N 1,1-dioxo-2-pyridin-2-yl-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound NC(=O)C1=CC2=CC=CC=C2S(=O)(=O)N1C1=CC=CC=N1 YNPZRWAUSSZALM-UHFFFAOYSA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000010531 varicella zoster infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010014290.5 | 2010-04-08 | ||
| DE102010014290A DE102010014290A1 (de) | 2010-04-08 | 2010-04-08 | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
| PCT/EP2011/001704 WO2011124366A1 (de) | 2010-04-08 | 2011-04-06 | Piroxicam zur prophylaktischen und therapeutischen behandlung von herpes - infektionen |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2013523789A JP2013523789A (ja) | 2013-06-17 |
| JP2013523789A5 JP2013523789A5 (enExample) | 2013-12-26 |
| JP6158077B2 JP6158077B2 (ja) | 2017-07-05 |
| JP6158077B6 true JP6158077B6 (ja) | 2018-08-29 |
Family
ID=43970974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013503032A Expired - Fee Related JP6158077B6 (ja) | 2010-04-08 | 2011-04-06 | ヘルペス感染症の予防措置及び治療措置のためのピロキシカム |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130190301A1 (enExample) |
| EP (1) | EP2374461B1 (enExample) |
| JP (1) | JP6158077B6 (enExample) |
| CN (1) | CN103153312B (enExample) |
| CA (1) | CA2795334C (enExample) |
| DE (1) | DE102010014290A1 (enExample) |
| DK (1) | DK2374461T3 (enExample) |
| ES (1) | ES2612584T3 (enExample) |
| PL (1) | PL2374461T3 (enExample) |
| RU (1) | RU2555765C2 (enExample) |
| WO (1) | WO2011124366A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
| DE102013003756A1 (de) | 2013-03-06 | 2014-09-11 | DeaValorum UG (haftungsbeschränkt) | Piroxicam zur prophylaktischen und therapeutischen Behandlung von CMV-Infektionen |
| DE102013014787A1 (de) | 2013-09-09 | 2015-03-12 | Dauphine UG (haftungsbeschränkt) | Mittel zur prophylaktischen und therapeutischen Behandlung von EHV-Infektionen |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3437232A1 (de) * | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| IT1216686B (it) * | 1988-04-01 | 1990-03-08 | Chiesi Farma Spa | Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione. |
| IT1230922B (it) * | 1989-06-23 | 1991-11-08 | Giuseppe De Benedittis | Composizione per il trattamento della nevralgia erpetica acuta e della nevralgia post erpetica |
| ATE95421T1 (de) * | 1990-04-26 | 1993-10-15 | Sagitta Arzneimittel Gmbh | Piroxicam enthaltende pharmazeutische zusammensetzung zur topischen anwendung. |
| JP3031990B2 (ja) * | 1990-10-19 | 2000-04-10 | 同仁医薬化工株式会社 | 消炎鎮痛クリーム剤組成物 |
| RU2182016C2 (ru) * | 1997-03-20 | 2002-05-10 | Панацея Биотек Лтд. | Спазмолитическая композиция, способ получения спазмолитической композиции |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| US7132452B2 (en) | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
-
2010
- 2010-04-08 DE DE102010014290A patent/DE102010014290A1/de not_active Ceased
-
2011
- 2011-03-04 EP EP11001816.5A patent/EP2374461B1/de active Active
- 2011-03-04 ES ES11001816.5T patent/ES2612584T3/es active Active
- 2011-03-04 DK DK11001816.5T patent/DK2374461T3/en active
- 2011-03-04 PL PL11001816T patent/PL2374461T3/pl unknown
- 2011-04-06 RU RU2012147474/15A patent/RU2555765C2/ru active
- 2011-04-06 CN CN201180021384.XA patent/CN103153312B/zh not_active Expired - Fee Related
- 2011-04-06 WO PCT/EP2011/001704 patent/WO2011124366A1/de not_active Ceased
- 2011-04-06 CA CA2795334A patent/CA2795334C/en active Active
- 2011-04-06 US US13/639,357 patent/US20130190301A1/en not_active Abandoned
- 2011-04-06 JP JP2013503032A patent/JP6158077B6/ja not_active Expired - Fee Related
-
2014
- 2014-01-29 US US14/167,676 patent/US20140148447A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2795334C (en) | 2015-06-09 |
| DK2374461T3 (en) | 2017-02-06 |
| US20140148447A1 (en) | 2014-05-29 |
| CA2795334A1 (en) | 2011-10-13 |
| WO2011124366A1 (de) | 2011-10-13 |
| JP6158077B2 (ja) | 2017-07-05 |
| JP2013523789A (ja) | 2013-06-17 |
| RU2555765C2 (ru) | 2015-07-10 |
| DE102010014290A1 (de) | 2011-10-13 |
| CN103153312B (zh) | 2015-07-22 |
| CN103153312A (zh) | 2013-06-12 |
| US20130190301A1 (en) | 2013-07-25 |
| EP2374461B1 (de) | 2016-10-26 |
| ES2612584T3 (es) | 2017-05-17 |
| RU2012147474A (ru) | 2014-05-20 |
| EP2374461A1 (de) | 2011-10-12 |
| PL2374461T3 (pl) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| EP2635269B1 (en) | A combination composition | |
| JP6313413B2 (ja) | アナフィラキシーの処置におけるレボセチリジン及びモンテルカストの使用 | |
| US20180169175A1 (en) | Formulations for the treatment of disorders of the mouth, throat and respiratory tract | |
| WO2007110356A1 (en) | Spray composition for topical use for treating and/or preventing herpes simplex labial infections | |
| JP6158077B2 (ja) | ヘルペス感染症の予防措置及び治療措置のためのピロキシカム | |
| Eby et al. | Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols | |
| JP2008543885A (ja) | 皮膚病変治療用組成物 | |
| Bernatoniene et al. | Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to< 12 years: APeX-P interim results | |
| US20230089715A1 (en) | Masitinib for the treatment of a multiple sclerosis patient subpopulation | |
| US20090062315A1 (en) | Pharmaceutical Acceptable Composition Containing Non-Steroidal Anti-Inflammatory Drug and Local Anesthetics | |
| JP2006515361A (ja) | ヘルペスウイルス感染の症候を治療又は予防する方法 | |
| ES2447829T3 (es) | Combinación para el tratamiento de la osteoartritis | |
| WO2015072853A1 (en) | Treatment of herpes virus infection outbreaks | |
| CA2921021C (en) | Methods and compositions for increasing the effectiveness of antiviral agents | |
| CN106361737A (zh) | 曲尼司特在制备治疗结核病的药物中的应用 | |
| KR20230018481A (ko) | 질병의 치료를 위한 2-(다이에틸아미노)에틸 2-(4-아이소부틸페닐)프로피오네이트의 국소 투여 | |
| US11951082B2 (en) | Composition of chlorhexidine | |
| Mahler | Herpes simplex | |
| CN103301115B (zh) | 一种治疗癫痫的药物组合物 | |
| Kaur et al. | Recurrent apthous stomatitis-a review | |
| US20060287364A1 (en) | Methods of prevention of infection with HIV/AIDS, venereal disease and influenza | |
| AU2008241370B2 (en) | Essential oil of kunzea ambigua and methods of use | |
| WO2016090316A1 (en) | Composition and method for treating bipolar disorder | |
| EA049592B1 (ru) | СПОСОБ ЛЕЧЕНИЯ РНК ВИРУСНЫХ ИНФЕКЦИЙ, В ТОМ ЧИСЛЕ COVID-19 (SARS-CoV-2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150303 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150319 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151014 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151021 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20151127 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170306 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6158077 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |